| Literature DB >> 30587154 |
Jin-Kyu Cho1, Young Min Choi2, Sang Soo Lee3,4,5, Hye Kyong Park6, Ra Ri Cha2,6, Wan Soo Kim2,6, Jin Joo Kim2,6, Jae Min Lee2,7,6, Hong Jun Kim2,7, Chang Yoon Ha2,7, Hyun Jin Kim2,7,6, Tae Hyo Kim2,7, Woon Tae Jung2,7, Ok Jae Lee2,7.
Abstract
BACKGROUND: Abdominal tuberculosis (TB) is an uncommon form of infection with Mycobacterium tuberculosis in Korea. In this study, we aimed to highlight the clinical features, diagnostic methods, and outcomes of abdominal TB over 12 years in Southeastern Korea.Entities:
Keywords: Abdomen; Extra-pulmonary; Luminal; Peritoneal; Tuberculosis
Mesh:
Year: 2018 PMID: 30587154 PMCID: PMC6307147 DOI: 10.1186/s12879-018-3635-2
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Sites of abdominal tuberculosis (TB)
Site of involvement in abdominal tuberculosis (n = 139)
| Site | N (%) |
|---|---|
| Luminal TB | |
| Esophageal | 3 (3.9%) |
| Stomach | 0 (0%) |
| Duodenal | 3 (3.9%) |
| Jejunal | 7 (9.2%) |
| Ileocecal | 51 (67.1%) |
| Colorectal | 12 (15.8%) |
| Peritoneal TB | |
| Wet ascitic type | 28 (75.7%) |
| Dry ascitic type | 9 (24.3%) |
| Nodal TB | |
| Mesenteric | 2 (14.3%) |
| Porta hepatis | 5 (35.7%) |
| Along the celiac axis | 1 (7.1%) |
| Peripancreatic | 2 (14.3%) |
| Retroperitoneal | 1 (7.1%) |
| Combined | 3 (21.4%) |
| Visceral TB | |
| Hepatic | 3 (10.3%) |
| Splenic | 4 (13.8%) |
| Genitourinary | 20 (69.0%) |
| Adrenal | 1 (3.4%) |
| Combined | 1 (3.4%) |
| Mixed TB | |
| Luminal and peritoneal | 4 (33.3%) |
| Luminal and nodal | 1 (8.3%) |
| Luminal and peritoneal, and nodal | 2 (16.7%) |
| Peritoneal and visceral | 2 (16.7%) |
| Nodal and visceral | 2 (16.7%) |
| Peritoneal and visceral, and nodal | 1 (8.3%) |
TB: tuberculosis
Data are presented as the median (interquartile range) for continuous data and percentages for categorical data
Demographic characteristics of 139 patients with abdominal tuberculosis
| Characteristic | All patients ( | Luminal TB ( | Peritoneal TB ( | Nodal TB ( | Visceral TB ( | Mixed TB ( |
|---|---|---|---|---|---|---|
| Age | 47.0 (32.0–58.0) | 48.0 (38.5–58.5) | 52.5 (27.3–63.0) | 53.0 (27.0–57.0) | 46.0 (33.0–56.0) | 32.0 (25.5–45.8) d, g, j |
| Male sex | 72 (51.8%) | 36 (52.2%) | 18 (64.3%) | 3 (42.9%) | 9 (39.1%) | 6 (50%) |
| BMI (m/kg2) | 21.80 (19.56–24.53) | 21.3 (19.6–24.1) | 21.6 (19.3–24.5) | 23.7 (20.1–27.8) | 20.1 (22.8–25.3) | 20.8 (18.0–22.8) |
| Chronic hepatitis B | 10 (7.2%) | 5 (7.2%) | 2 (7.1%) | 0 (0%) | 2 (8.7%) | 1 (8.3%) |
| Chronic hepatitis C | 3 (2.2%) | 1 (1.4%) | 0 (0%) | 2 (28.6%) b, e, h | 0 (0%) | 0 (0%) |
| HIV-infection | 2 (1.4%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4.3%) | 1 (8.3%) |
| Alcohol > 40 g/day | 16 (11.5%) | 6 (8.7%) | 6 (21.4%) | 0 (0%) | 2 (8.7%) | 2 (16.7%) |
| Cirrhosis | 3 (2.2%) | 2 (2.9%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (8.3%) |
| Diabetes | 9 (6.5%) | 3 (4.3%) | 3 (10.7%) | 1 (14.3%) | 2 (8.7%) | 0 (0%) |
| ESRD or CAPD | 8 (5.8%) | 3 (4.3%) | 3 (10.7%) | 1 (14.3%) | 1 (4.3%) | 0 (0%) |
| History of malignancy | 7 (5.0%) | 3 (4.3%) | 2 (7.1%) | 0 (0%) | 2 (8.7%) | 0 (0%) |
| History of TB | 13 (9.4%) | 7 (10.1%) | 0 (0%) | 1 (14.3%) | 5 (21.7%) f | 0 (0%) |
| Anemia at diagnosis | 46 (33.1%) | 21 (30.4%) | 11 (39.3%) | 3 (42.9%) | 5 (21.7%) | 6 (50.0%) |
| Leukocytosis at diagnosis | 30 (21.6%) | 16 (23.2%) | 3 (10.7%) | 3 (42.9%) | 3 (13.0%) | 5 (41.7%) g |
HIV: human immunodeficiency virus; ESRD: end-stage renal disease; CAPD: continuous ambulatory peritoneal dialysiData are presented as the median (interquartile range) for continuous data and percentages for categorical data
Defined as hemoglobin of 12 g/dl
Defined as a white blood cell count of 10,000/mm3
a: P < 0.05 Luminal TB vs. Peritoneal TB, b: P < 0.05 Luminal TB vs. Nodal TB, c: P < 0.05 Luminal TB vs. Visceral TB, d: P < 0.05 Luminal TB vs. Mixed TB, e: P < 0.05 Peritoneal TB vs. Nodal TB, f: P < 0.05 Peritoneal TB vs. Visceral TB, g: P < 0.05 Peritoneal TB vs. Mixed TB, h: P < 0.05 Nodal TB vs. Visceral TB, i: P < 0.05 Nodal TB vs. Mixed TB, j: P < 0.05 Visceral TB vs. Mixed TB
Clinical features in 139 patients with abdominal tuberculosis
| Characteristic | All patients ( | Luminal TB ( | Peritoneal TB ( | Nodal TB ( | Visceral TB ( | Mixed TB ( |
|---|---|---|---|---|---|---|
| Abdominal pain | 48 (34.5%) | 23 (33.3%) | 7 (25.0%) | 3 (42.9%) | 9 (39.1%) | 6 (50.0%) |
| Fever | 16 (11.5%) | 5 (7.2%) | 6 (21.4%) | 0 (0%) | 3 (13.0%) | 2 (16.7%) |
| Anorexia | 9 (6.5%) | 6 (8.7%) | 1 (3.6%) | 1 (14.3%) | 0 (0%) | 1 (8.3%) |
| Body weight loss | 5 (3.6%) | 4 (5.8%) | 1 (3.6%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Abdominal distension | 29 (21.0%) | 2 (2.9%) | 22 (78.6%) a, e, f, g | 0 (0%) | 0 (0%) | 5 (41.7%) d, j |
| Bloody stool | 11 (7.9%) | 10 (14.5%) | 0 (0%) | 0 (0%) | 1 (4.3%) | 0 (0%) |
| Dyspnea | 2 (1.4%) | 0 (0%) | 1 (3.6%) | 0 (0%) | 1 (4.3%) | 0 (0%) |
| Diarrhea | 6 (4.3%) | 5 (7.2%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (8.3%) |
| Hematuria | 1 (0.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4.3%) | 0 (0%) |
| Dysuria | 2 (1.4%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (8.7%) | 0 (0%) |
| Palpable mass | 3 (2.2%) | 1 (1.4%) | 0 (0%) | 1 (14.3%) | 1 (4.3%) | 0 (0%) |
| Scrotal swelling | 1 (0.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4.3%) | 0 (0%) |
| Jaundice | 1 (0.7%) | 0 (0%) | 0 (0%) | 1 (14.3%) | 0 (0%) | 0 (0%) |
| No symptom | 31 (22.3%) | 23 (33.3%) a, d | 1 (3.6%) | 2 (28.6%) | 5 (21.7%) | 0 (0%) |
Data are presented as the median (interquartile range) for continuous data and percentages for categorical data
a: P < 0.05 Luminal TB vs. Peritoneal TB, b: P < 0.05 Luminal TB vs. Nodal TB, c: P < 0.05 Luminal TB vs. Visceral TB, d: P < 0.05 Luminal TB vs. Mixed TB, e: P < 0.05 Peritoneal TB vs. Nodal TB, f: P < 0.05 Peritoneal TB vs. Visceral TB, g: P < 0.05 Peritoneal TB vs. Mixed TB, h: P < 0.05 Nodal TB vs. Visceral TB, i: P < 0.05 Nodal TB vs. Mixed TB, j: P < 0.05 Visceral TB vs. Mixed TB
Diagnostic method in 139 patients with abdominal tuberculosis
| Characteristic | All patients ( | Luminal TB ( | Peritoneal TB ( | Nodal TB ( | Visceral TB ( | Mixed TB ( |
|---|---|---|---|---|---|---|
| Microbiologic diagnosis | 51 (37.0%) | 23 (33.3%) | 7 (25.0%) | 2 (28.6%) | 15 (68.2%) c, f | 4 (33.3%) |
| Histological diagnosis | 59 (42.8%) | 27 (39.1%) | 8 (28.6%) | 6 (85.7%) b, e | 12 (54.5%) | 6 (50.0%) |
| Clinical diagnosis | 63 (45.3%) | 35 (50.7%) c | 18 (64.3%) e, f | 1 (14.3%) | 3 (13.6%) | 6 (50.0%) j |
| Operation | 21 (15.1%) | 2 (2.9%) | 4 (14.3%) | 3 (42.9%) b | 10 (43.5%) c, f | 2 (16.7%) |
| *Confirmed diagnosis by operation | 19 (90.4%) | 2 (100%) | 4 (100%) | 3 (100%) | 9 (90%) | 1 (50%) |
| Percutaneous biopsy group | 16 (11.5%) | 0 (0%) a, b, c, d | 6 (21.4%) | 3 (42.9%) | 3 (13.0%) | 4 (33.3%) |
| *Confirmed diagnosis by percutaneous biopsy | 13 (81.3%) | 0/0 | 4 (66.7%) | 2 (66.7%) | 3 (100%) | 4 (100%) |
| Endoscopy or colonoscopy | 70 (50.4%) | 65 (94.2%) a, b, c, d | 0 (0%) | 0 (0%) | 0 (0%) | 4 (33.3%) g, j |
| *Confirmed diagnosis by endoscopy or colonoscopy | 34 (48.6%) | 32 (49.2%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (25%) |
| Paracentesis | 33 | 0 | 27 (96.4%) a, e, f, g | 0 | 0 | 6 (50.0%) g, j |
| *Confirmed diagnosis by paracentesis | 8 (24.2%) | 0 (0%) | 6 (21.4%) a,f | 0 (0%) | 0 (0%) | 2 (33.3%) d |
Data are presented as the median (interquartile range) for continuous data and percentages for categorical data
*A Confirmed diagnosis was defined as microbiologic or histological diagnosis
a: P < 0.05 Luminal TB vs. Peritoneal TB, b: P < 0.05 Luminal TB vs. Nodal TB, c: P < 0.05 Luminal TB vs. Visceral TB, d: P < 0.05 Luminal TB vs. Mixed TB, e: P < 0.05 Peritoneal TB vs. Nodal TB, f: P < 0.05 Peritoneal TB vs. Visceral TB, g: P < 0.05 Peritoneal TB vs. Mixed TB, h: P < 0.05 Nodal TB vs. Visceral TB, i: P < 0.05 Nodal TB vs. Mixed TB, j: P < 0.05 Visceral TB vs. Mixed TB
Treatment outcomes in 139 patients with abdominal tuberculosis
| Characteristic | All patients ( | Luminal TB ( | Peritoneal TB ( | Nodal TB ( | Visceral TB ( | Mixed TB ( |
|---|---|---|---|---|---|---|
| Duration of treatment, days | 194.0 (176.0–258.0) | 189.0 (175.0–219.0) | 200.0 (165.0–258.0) | 258.0 (16.0–285.0) | 284.0 (178.0–284.0) | 245.0 (177.5–349.0) |
| Side effect | 21 (15.2%) | 11 (15.9%) | 3 (11.1%) | 0 (0%) | 4 (17.4%) | 3 (25.0%) |
| Drug-induced liver injury | 9 (6.5%) | 5 (8.7%) | 2 (7.1%) | 0 (0%) | 0 (0%) | 1 (8.3%) |
| Nephrectomy | 4 (2.9%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (17.4%) c, f | 0 (0%) |
| First-line anti-TB drug | 131 (94.2%) | 66 (95.7%) | 27 (96.4%) | 7 (100%) | 20 (87.0%) | 11 (91.7%) |
| Second-line anti-TB drug | 8 (5.8%) | 3 (4.3%) | 1 (3.6%) | 0 (0%) | 3 (13.0%) | 1 (8.3%) |
| Complete response | 117 (84.2%) | 62 (89.9%) | 22 (78.6%) | 3 (42.9%) b, e, h, i | 20 (87.0%) | 10 (83.3%) |
| Partial response | 1 (0.7%) | 0 (0%) | 0 (0%) | 1 (14.3%) | 0 (0%) | 0 (0%) |
| No response | 2 (1.4%) | 1 (1.4%) | 0 (0%) | 0 (0%) | 1 (4.3%) | 0 (0%) |
| Lost to follow up | 12 (8.6%) | 4 (5.8%) | 5 (17.9%) | 0 (0%) | 1 (4.3%) | 2 (16.7%) |
| Recurrence | 3 (2.2%) | 1 (1.4%) | 1 (3.6%) | 1 (14.3%) | 0 (0%) | 0 (0%) |
| Transfer out | 3 (2.2%) | 1 (1.4%) | 0 (0%) | 2 (28.6%) | 0 (0%) | 0 (0%) |
| Death | 2 (1.4%) | 1 (1.4%) | 0 (0%) | 0 (0%) | 1 (4.3%) | 0 (0%) |
Data are presented as the median (interquartile range) for continuous data and percentages for categorical data
a: P < 0.05 Luminal TB vs. Peritoneal TB, b: P < 0.05 Luminal TB vs. Nodal TB, c: P < 0.05 Luminal TB vs. Visceral TB, d: P < 0.05 Luminal TB vs. Mixed TB, e: P < 0.05 Peritoneal TB vs. Nodal TB, f: P < 0.05 Peritoneal TB vs. Visceral TB, g: P < 0.05 Peritoneal TB vs. Mixed TB, h: P < 0.05 Nodal TB vs. Visceral TB, i: P < 0.05 Nodal TB vs. Mixed TB, j: P < 0.05 Visceral TB vs. Mixed TB
Fig. 2Cases of abdominal tuberculosis (TB), 2005–2008, 2009–2012, and 2013–2016, respectively. In 2010, incidence of abdominal TB tended to decrease